Authors


Robert Lübeck, Dr Med

Latest:

Performance of the Adapted Diabetes Complications Severity Index Translated to ICD-10

We present an International Classification of Diseases, Tenth Revision (ICD-10) translation of the adapted Diabetes Complications Severity Index and show its performance in predicting hospitalizations, mortality, and healthcare-associated costs.




Denise D. Quigley, PhD

Latest:

Telephone Follow-Up on Medicare Patient Surveys Remains Critical

Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.


Anita Wagner, PharmD

Latest:

Cost Burden of Hepatitis C Virus Treatment in Commercially Insured Patients

Rates of hepatitis C virus (HCV) treatment in a commercially insured population doubled after availability of new direct-acting antivirals. Member out-of-pocket spending was kept low while the health plan bore 99% of spending on HCV medications.




Kristin Stewart, MHSA

Latest:

Health Plan—Provider Accountable Care Partnerships: How Have They Evolved?

Although health plan accountable care models have evolved provider readiness, data, analytics, and the use of performance measurement are important components of plan-provider partnerships.


Thomas Power, MD

Latest:

Does CAC Testing Alter Downstream Treatment Patterns for Cardiovascular Disease?

This article provides an assessment of the downstream impact of coronary artery calcium scanning on the subsequent treatment patterns of non—high-risk patients.



David Tovey, FRCGP

Latest:

Comparative Effectiveness Research: Challenges for Medical Journals

In order to encourage dissemination, this commentary is freely available in PLoS Medicine, and will also be published in Medical Decision Making, Croatian Medical Journal, The Cochrane Library, Trials, and Journal of Clinical Epidemiology.


Marc Herant, PhD, MD

Latest:

The Value of Decreasing Health Cost Volatility

Even if they leave average cost the same, interventions that decrease cost variability have economic value.


Benjamin Gutierrez, PhD

Latest:

Relationship Between Short-Acting β-Adrenergic Agonist Use and Healthcare Costs

Overuse of rescue medication among asthma patients is associated with increased exacerbations and higher total and asthma-related healthcare costs.


Rachel Hess, MD, MS

Latest:

Benchmarking Health-Related Quality-of-Life Data From a Clinical Setting

Health-related quality-of-life data are often collected during routine clinical care. We present a method to create nationally representative benchmarks for clinical subspecialties.


Richard L. Brown, MD, MPH

Latest:

Lessons Learned in Implementing Behavioral Screening and Intervention

This article describes lessons learned over the past 10 years while helping several dozen primary care settings implement evidence-based, cost-saving behavioral screening and intervention.


Amy E. Wagie, BS

Latest:

Flunking Asthma? When HEDIS Takes the ACT

Asthma control, rather than compliance with the HEDIS asthma measure, is the most useful quality indicator of asthma care.


Saul Schaefer, MD

Latest:

Comparative Efficacy of Ezetimibe/Simvastatin, Rosuvastatin, and Atorvastatin in Uncontrolled Hyperlipidemia Patients

Efficacy of switching statin therapy from generic simvastatin was examined in a VA population. Ezetimibe/simvastatin was more potent than atorvastatin or rosuvastatin in lowering LDL.


Joshua S. Goldner, MD

Latest:

ED-Based Care Coordination Reduces Costs for Frequent ED Users

Results of our pilot randomized controlled intervention involving emergency department (ED)-based care coordination and community health workers demonstrated a trend toward fewer ED visits, fewer hospitalizations, and lower costs among intervention patients.


Sarah J. Billups, PharmD

Latest:

Out-of-Plan Pharmacy Use: Insights Into Patient Behavior

Prescription cost and pharmacy convenience were identified as the most significant drivers of out-of-plan pharmacy use.


Francois de Brantes, MBA

Latest:

The Value of Ambulatory Care Measures: A Review of Clinical and Financial Impact from an Employer/Payer Perspective

This review suggests that only a few primary care quality measures, which usually are not found in claims data, have significant clinical and financial impact.


David Aron, MD, MS

Latest:

E-Consult Implementation: Lessons Learned Using Consolidated Framework for Implementation Research

This paper identified 4 factors associated with implementation success of e-consults in 8 VA medical centers, with implications for implementing similar health IT initiatives elsewhere.






Frederick J. Bloom Jr, MD

Latest:

Primary Care Diabetes Bundle Management: 3-Year Outcomes for Microvascular and Macrovascular Events

Using a system for primary care management of patients with diabetes may reduce the risk of myocardial infarction, stroke, and retinopathy over a 3-year period.


John P. Williams, MD

Latest:

The Value of Ambulatory Care Measures: A Review of Clinical and Financial Impact from an Employer/Payer Perspective

This review suggests that only a few primary care quality measures, which usually are not found in claims data, have significant clinical and financial impact.


Susan Brownlee, PhD

Latest:

Hospital Responses to DSRIP Program Reforms in New Jersey

This study examines the New Jersey Delivery System Reform Incentive Payment (DSRIP) program using hospital web surveys and key informant interviews and finds progress toward data-driven population health management for low-income patients.


Louis M. Kwong, MD

Latest:

Analysis of Venous Thromboprophylaxis Duration and Outcomes in Orthopedic Patients

Extended-duration thromboprophylaxis (>14 days) for total hip replacement/total knee replacement was associated with significantly lower risk for thromboembolic and bleeding events than short-duration thromboprophylaxis.


Junji Lin, PhD, MS

Latest:

Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia

This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo